» Articles » PMID: 27602171

Identification of a Methylation Profile for DNMT1-associated Autosomal Dominant Cerebellar Ataxia, Deafness, and Narcolepsy

Overview
Publisher Biomed Central
Specialty Genetics
Date 2016 Sep 8
PMID 27602171
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: DNA methylation is an essential epigenetic mark, controlled by DNA methyltransferase (DNMT) proteins, which regulates chromatin structure and gene expression throughout the genome. In this study, we describe a family with adult-onset autosomal dominant cerebellar ataxia with deafness and narcolepsy (ADCA-DN) caused by mutations in the maintenance methyltransferase DNMT1 and assess the DNA methylation profile of these individuals.

Results: We report a family with six individuals affected with ADCA-DN; specifically, patients first developed hearing loss and ataxia, followed by narcolepsy, and cognitive decline. We identified a heterozygous DNMT1 variant, c.1709C>T [p.Ala570Val] by Sanger sequencing, which had been previously reported as pathogenic for ADCA-DN and segregated with disease in the family. DNA methylation analysis by high-resolution genome-wide DNA methylation array identified a decrease in CpGs with 0-10 % methylation and 80-95 % methylation and a concomitant increase in sites with 10-30 % methylation and >95 % methylation. This pattern suggests an increase in methylation of normally unmethylated regions, such as promoters and CpG islands, as well as further methylation of highly methylated gene bodies and intergenic regions. Furthermore, a regional analysis identified 82 hypermethylated loci with consistent robust differences across ≥5 consecutive probes compared to our large reference cohort.

Conclusions: This report identifies robust changes in the DNA methylation patterns in ADCA-DN patients, which is an important step towards elucidating disease pathogenesis.

Citing Articles

Whole Blood DNA Methylation Analysis Reveals Epigenetic Changes Associated with ARSACS.

De Riso G, Naef V, Damiani D, Doccini S, Santorelli F, Galatolo D Cerebellum. 2025; 24(2):36.

PMID: 39853590 DOI: 10.1007/s12311-025-01791-5.


Oxidative Effects in Early Stages of Embryo Development Due to Alcohol Consumption.

Gonzalez-Flores D, Marquez A, Casimiro I Int J Mol Sci. 2024; 25(7).

PMID: 38612908 PMC: 11012856. DOI: 10.3390/ijms25074100.


The Importance of Offering Exome or Genome Sequencing in Adult Neuromuscular Clinics.

Dratch L, Bardakjian T, Johnson K, Babaian N, Gonzalez-Alegre P, Elman L Biology (Basel). 2024; 13(2).

PMID: 38392311 PMC: 10886886. DOI: 10.3390/biology13020093.


Disease-Associated Mutation A554V Disrupts Normal Autoinhibition of DNMT1.

Switzer R, Hartman Z, Hewett G, Carroll C DNA (Basel). 2023; 3(3):119-133.

PMID: 37663147 PMC: 10470860. DOI: 10.3390/dna3030010.


Mutations in human DNA methyltransferase DNMT1 induce specific genome-wide epigenomic and transcriptomic changes in neurodevelopment.

Davis K, Qu P, Ma S, Lin L, Plastini M, Dahl N Hum Mol Genet. 2023; 32(21):3105-3120.

PMID: 37584462 PMC: 10586194. DOI: 10.1093/hmg/ddad123.


References
1.
Scarano M, Strazzullo M, Matarazzo M, DEsposito M . DNA methylation 40 years later: Its role in human health and disease. J Cell Physiol. 2005; 204(1):21-35. DOI: 10.1002/jcp.20280. View

2.
Melberg A, Dahl N, Hetta J, Valind S, Nennesmo I, Lundberg P . Neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy. Neurology. 1999; 53(9):2190-2. DOI: 10.1212/wnl.53.9.2190. View

3.
Schenkel L, Schwartz C, Skinner C, Rodenhiser D, Ainsworth P, Pare G . Clinical Validation of Fragile X Syndrome Screening by DNA Methylation Array. J Mol Diagn. 2016; 18(6):834-841. DOI: 10.1016/j.jmoldx.2016.06.005. View

4.
Sun Z, Wu Y, Ordog T, Baheti S, Nie J, Duan X . Aberrant signature methylome by DNMT1 hot spot mutation in hereditary sensory and autonomic neuropathy 1E. Epigenetics. 2014; 9(8):1184-93. PMC: 4164503. DOI: 10.4161/epi.29676. View

5.
Schenkel L, Rodenhiser D, Ainsworth P, Pare G, Sadikovic B . DNA methylation analysis in constitutional disorders: Clinical implications of the epigenome. Crit Rev Clin Lab Sci. 2016; 53(3):147-65. DOI: 10.3109/10408363.2015.1113496. View